You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tremelimumab

Showing 1 - 25 of 104
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 27, 2022

Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • +2 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Jan 18, 2023

Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)

Not yet recruiting
  • Borderline Resectable Carcinoma
  • Biliary Tract Cancer
  • Washington, District of Columbia
    Lombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023

Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)

Active, not recruiting
  • Metastatic
  • +4 more
  • Radiotherapy
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 6, 2023

Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed

Completed
Has Results
  • Metastatic Breast Cancer
  • Brain radiotherapy or Stereotactic Radiosurgery
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 2, 2022

Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Available
  • Unresectable Hepatocellular Carcinoma
  • (no location specified)
Aug 12, 2022

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

Multiple Myeloma Trial in New York (Tremelimumab, Durvalumab, Prevnar-13)

Terminated
Has Results
  • Multiple Myeloma
  • Tremelimumab
  • +3 more
  • New York, New York
  • +1 more
Oct 3, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Nonsmall Cell Lung Cancer Trial in New York (Durvalumab, Tremelimumab)

Not yet recruiting
  • Nonsmall Cell Lung Cancer
  • New York, New York
    Columbia University Irving Medical Center
Apr 29, 2022

Urothelial Carcinoma Trial in Amsterdam (Tremelimumab, Durvalumab, Paclitaxel)

Active, not recruiting
  • Urothelial Carcinoma
  • Tremelimumab
  • +2 more
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek Ziekenhuis
Jul 7, 2022

Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)

Active, not recruiting
  • Metastatic Melanoma
  • Boston, Massachusetts
  • +1 more
Mar 22, 2022

Mesothelioma Trial in Houston (MEDI4736, Tremelimumab, no other name)

Active, not recruiting
Has Results
  • Mesothelioma
  • Houston, Texas
    Baylor St Lukes
Jan 25, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston

Recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • +3 more
  • Durvalumab
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Oct 10, 2022

Tumors Trial in Australia, Canada, United States (feladilimab, Tremelimumab, Docetaxel)

Completed
Has Results
  • Neoplasms
  • Boston, Massachusetts
  • +7 more
Jul 28, 2022

Hepatocellular Carcinoma Trial in Toronto, Milan, Pamplona (Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Tremelimumab
  • Toronto, Ontario, Canada
  • +2 more
Jun 27, 2022

Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)

Completed
  • Endometrial Cancer
  • +4 more
  • Basking Ridge, New Jersey
  • +6 more
Jan 3, 2023

Bladder Cancer, High-Risk Cancer, Tremelimumab Trial in Vancouver (Tremelimumab)

Recruiting
  • Bladder Cancer
  • +4 more
  • Tremelimumab
  • Vancouver, British Columbia, Canada
    Vancouver General Hospital
Nov 3, 2021

Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension Trial in Cincinnati (Durvalumab, Tremelimumab, Liver Transplant)

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Cincinnati, Ohio
    University of Cincinnati
Dec 8, 2021

Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)

Active, not recruiting
  • Biliary Tract Neoplasms
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Oct 26, 2021

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
Has Results
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Metastatic or Locally Advanced NSCLC Trial in Ramat Gan (Durvalumab, Tremelimumab, Low dose irradiation)

Recruiting
  • Metastatic or Locally Advanced NSCLC
  • Ramat Gan, Israel
    Sheba Medical Centre
Jan 9, 2022